Hi guys! So lately theres been some buzz on a particular variant, increased cases of hospitalizations and government backing. At risk population that require vaccinations/ boosters will always exist. Therefore, i believe this fact along with various technical analysis findings can make companies such as Biontech, Moderna and even not as famous Novavax potential...
Moderna Inc (MRNA), a much discussed stock over the previous years, is having a +8% day, a very encouraging since following the rejection on the 1D MA50 (blue trend-line) three days ago. What's more interesting is that we have seen almost the same pattern in the stock's all time lows in 2019. As you see, the price since September has been on Lower Lows while the...
Pfizer has ER next week and 5/20 calls sweeping today Technically it looks like we can get a run up to ER , as PFE is at trendline support and possible "fill out" of the triangle pattern Any run up will capture some gains, will trim position and leave a few runners for ER. Sweeps were 55.5 and 57 strike which are pretty far out the money, worth noting. Could...
pfizer is one of those household names that has been getting constant attention since the outbreak of covid 19. right now it is at the tail end of a long downtrend, and healthcare is acting as a defensive play for risk off rotation. as long as the broader market bounces this should bounce.
novavax blew up after announcing it was making a covid vaccine. they eventually parléd this into a montly uptrend that lasted until september '21. since then it has seen a major decline. the stock is attempting to end that now, or at least find a temporary rally from new multi year lows. this could lead to a short squeeze zipping the price back up towards weekly...
They have marked the supports and resistances of ALNOV. It has great upside potential, key level reaching $ 5 Last Friday news Clinical diagnostics specialist Novacyt announced on Friday thatots ‘genesig’ Covid-19 real-time PCR test has been approved in the UK. I send you a cordial greeting, Merry Christmas and a prosperous 2022 In Spain on 12/23/2021
Short $RCL CMP $79.21. Heavily affected by Covid news. Recent lockdown news in EU dragging the price down. Stock price is below 200 SMA . $75 area may act as support but heavy selling may take further down to $65 area in near future.
European Commission’s independent experts selected Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19! CEO of Humanigen said today: "We look forward to continuing our discussions with colleagues at the European Medicines Agency to advance our efforts to submit a marketing authorization application for lenzilumab in COVID-19". In the...
Target price $10, after hitting a 52 week low, IMVT is looking good for a bounce.
Biotech sector is getting hot, especially for companies connected to COVID-19 vaccine and treatments development... BIOV chart looks rip for a breakout with MACD closing in on bullish cross and a major catalyst in the form of FDA approval of its Phase I/II study: FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical...
KNR has been beaten down but looks way overdone, given they have just raised $8.5 at 1.50 with institutional investors. The company reported respectable $3.3M revenues in Q1 2021. Their BioCloud COVID-19 detection device will be used by the Canadian Olympic delegation at the Tokyo Olympics. The US sales channel is being worked on. Insiders are buying in the open...
Idea for Chemomab Therapeutics Ltd.: - 131% borrow fee for shares. 47 shares available for borrow, according to iborrowdesk. - Bottom of Risk Range: - S3 Filing Sales Agreement with Cantor Fitzgerald & Co. dated Apr 30, 2021. fintel.io - Cantor Fitzgerald assigned overweight rating on CMMB and raised price target to $45. www.marketbeat.com - Good short squeeze...
Crude above red line has failed multiple times, but, you can see the 'rising lows' that are now crowding the red line. My thesis has supply chaos (that is happening everywhere we look) coming to the energy space. If this becomes true: --Long XOP stocks --Long TSLA --Short IWM
Surprisingly enough this company is stellar when you look at the financials. Its Cash Cycle is under 30 days with absolutely NO ACCOUNTS RECIEVABLE!!! its been growing its revenue around 10% each year, management has been buying back shares to increase shareholder equity, its dividends are squat :( , but they are gunning for Five and Below/ FIVE s market by...
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg - Company secures next step to continue to build-out pipeline of assets. - University researchers developed a proprietary and orally active bacterial vaccine...
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19 announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific...
Watch this stock move as new countries, states consider/announce shutdowns.
Highlights for Q3 2020 • Annual group sales exceed 100 MNOK for the first time • Gross profit for the Group improved 65% to NOK 26.0 million (Q3 2019: NOK 15.7 million) • ArcticZymes had Q3 sales of NOK 19.5 million growing by 63% (Q3 2019: NOK 12.0 million) • Biotec BetaGlucans had Q3 sales of NOK 11.2 million growing by 7% (Q3 2019: NOK 10.5 million) • Upsides...